|1.||Bolter, Chris P: 3 articles (10/2011 - 01/2008)|
|2.||Nattel, Stanley: 2 articles (01/2008 - 04/2006)|
|3.||Nishida, Hirofumi: 1 article (01/2014)|
|4.||Nakamura, Atsushi: 1 article (01/2014)|
|5.||Ro, J Y: 1 article (01/2014)|
|6.||Suzuki, Tsutomu: 1 article (01/2014)|
|7.||Ogawa, Koichi: 1 article (01/2014)|
|8.||Suzuki, Kazumasa: 1 article (01/2014)|
|9.||Cho, Y S: 1 article (01/2014)|
|10.||Matsumoto, Akio: 1 article (01/2014)|
|1.||Osteosarcoma (Osteogenic Sarcoma)
01/01/2008 - "Atrial tachycardia increases agonist-independent constitutive I K,ACh single-channel activity by enhancing spontaneous channel opening, providing a molecular basis for AT effects on macroscopic I K,ACh observed in previous studies, as well as associated refractoriness abbreviation and tertiapin-suppressible AF promotion. "
04/11/2006 - "This study assessed the role of IKH in atrial tachycardia (AT)-remodeled canine left atrium (LA) with the use of tertiapin-Q as a probe. "
04/11/2006 - "In AT-remodeled preparations, tachyarrhythmia duration averaged 11.0+/-5.2 seconds, with a cycle length of 108+/-6 ms. Tertiapin-Q decreased tachyarrhythmia duration (to 0.6+/-0.1 second; P<0.001) and increased tachyarrhythmia cycle length (to 175+/-10 ms; P<0.001). "
04/11/2006 - "In 2 AT-remodeled preparations, tachyarrhythmia lasted uninterrupted for >20 minutes; tertiapin-Q slowed and then terminated arrhythmia in both. "
04/11/2006 - "AT remodeling increases IKH, and a highly selective Kir3 current antagonist, tertiapin-Q, increases APD and suppresses atrial tachyarrhythmias in AT-remodeled preparations without affecting ventricular electrophysiology. "
10/28/2011 - "experimental data shows that small and modest vagal bradycardia is accompanied by hyperpolarisation of the pacemaker cell which is severely attenuated by tertiapin-Q. "
10/05/2009 - "In tertiapin-Q, vagal bradycardia displayed a gradual onset and offset, with a peak response ~50% of that recorded in control conditions. "
10/05/2009 - "Subsequent cumulative addition of tertiapin-Q had no additional effect on baseline atrial rate, but caused further reduction in the amplitude of vagal bradycardia, suggesting that 1 mM Ba(2+) did not achieve a complete block of I(K,ACh) in this preparation."
10/05/2009 - "In a separate set of experiments we compared the effects of 1 mM Ba(2+) and 300 nM tertiapin-Q on vagal bradycardia. "
01/01/2008 - "Acetylcholine (3 nmol) produced brief graded bradycardias that were also attenuated by tertiapin-Q (0.24 +/- 0.24; P = 0.006). "
08/01/2006 - "Tertiapin, a selective IKACh blocker, terminates atrial fibrillation with selective atrial effective refractory period prolongation."
01/01/2014 - "Recently it has been demonstrated that tertiapin, a selective blocker of KACh channel, suppressed aconitine-induced atrial fibrillation (AF) in dogs. "
01/01/2014 - "Termination of aconitine-induced atrial fibrillation by the KACh-channel blocker tertiapin: underlying electrophysiological mechanism."
|1.||Morphine (MS Contin)
|2.||Acetylcholine (Acetylcholine Chloride)
|3.||D-Penicillamine (2,5)- Enkephalin
|8.||Bee Venoms (Bee Venom)
|10.||N-methyl-valyl-amiclenomycin (BA 2)